Literature DB >> 18696119

Effects of pegylated interferon alpha-2a on hepatitis-C-virus-associated glomerulonephritis.

Tokio Sugiura1, Takuji Yamada, Yuri Kimpara, Naoya Fujita, Kenji Goto, Norihisa Koyama.   

Abstract

Hepatitis C virus (HCV) infection leads to chronic liver disease, but it has also been associated with extrahepatic manifestations. Membranoproliferative glomerulonephritis (MPGN) is the most common renal disease associated with HCV. Although renal disease related to HCV in adults has been well studied, it has not been well studied in children because it is rare. A recent study found that antiviral therapy was effective for adult patients with HCV-associated MPGN. We report a 9-year-old girl with HCV-associated MPGN. Her HCV genotype was 1b, and her virus load was high. The first renal biopsy showed mesangial proliferation and partial double contours of the basement membrane on light microscopy and immunofluorescence staining with immunoglobulin (Ig) M, IgG, and C3. The patient was successfully treated with pegylated interferon (IFN) alpha-2a monotherapy. The antiviral therapy was generally well tolerated. After antiviral therapy, a sustained virological response-defined as negative HCV ribonucleic acid (RNA) at least 24 weeks after antiviral treatment-was achieved, the proteinuria disappeared, and the second renal biopsy showed improvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18696119     DOI: 10.1007/s00467-008-0948-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  13 in total

1.  Interferon treatment on glomerulonephritis associated with hepatitis C virus.

Authors:  S Matsumoto; S Nakajima; K Nakamura; Y Etani; H Hirai; N Shimizu; H Yokoyama; Y Kobayashi; H Tajiri; M Shima; S Okada
Journal:  Pediatr Nephrol       Date:  2000-12       Impact factor: 3.714

Review 2.  Hepatitis C and renal disease: an update.

Authors:  Catherine M Meyers; Leonard B Seeff; Catherine O Stehman-Breen; Jay H Hoofnagle
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

Review 3.  Peginterferon and ribavirin for chronic hepatitis C.

Authors:  Jay H Hoofnagle; Leonard B Seeff
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

4.  Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children.

Authors:  P Tarshish; J Bernstein; J N Tobin; C M Edelmann
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

5.  Homology of E2 gene in 8 child-mother pairs infected with hepatitis C virus.

Authors:  R Li; K Sugiyama; K Goto; Y Miyake; Y Wada
Journal:  Tohoku J Exp Med       Date:  1997-11       Impact factor: 1.848

6.  Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

Authors:  Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullmer; Patrick Gerner; Philip Wintermeyer; Andreas Jenke
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

7.  Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  D Sansonno; L Gesualdo; C Manno; F P Schena; F Dammacco
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

8.  Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

Authors:  Kathleen B Schwarz; Parvathi Mohan; Michael R Narkewicz; Jean Pappas Molleston; S Russell Nash; Sylvia Hu; Ka Wang; Jean Michel Gries
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-10       Impact factor: 2.839

9.  Second generation hepatitis C virus antibody-positive rate in children: investigation of the route of hepatitis C virus infection in children with no history of transfusion.

Authors:  H Maniwa; Y Miyake; T Oda; R Li; T Yokoyama; K Sugiyama
Journal:  Acta Paediatr Jpn       Date:  1997-10

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  5 in total

Review 1.  Treatment of hepatitis C in children and adolescents: how far have we reached?

Authors:  Vybhav Venkatesh; Keerthivasan Seetharaman; Neha Anushree
Journal:  World J Pediatr       Date:  2022-09-21       Impact factor: 9.186

Review 2.  Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression.

Authors:  Pier-Angelo Tovo; Carmelina Calitri; Carlo Scolfaro; Clara Gabiano; Silvia Garazzino
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 3.  Autoimmunity and extrahepatic manifestations in treatment-naïve children with chronic hepatitis C virus infection.

Authors:  Giuseppe Indolfi; Elisa Bartolini; Biagio Olivito; Chiara Azzari; Massimo Resti
Journal:  Clin Dev Immunol       Date:  2012-05-08

Review 4.  Hepatitis C virus infection in children and adolescents.

Authors:  James E Squires; William F Balistreri
Journal:  Hepatol Commun       Date:  2017-03-23

Review 5.  Breakthroughs and challenges in the management of pediatric viral hepatitis.

Authors:  Emanuele Nicastro; Lorenzo Norsa; Angelo Di Giorgio; Giuseppe Indolfi; Lorenzo D'Antiga
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.